Last Updated: 14 Nov 2024
Executive Summary
Cellectis SA (CLLS) is a clinical-stage biotechnology company developing immuno-oncology products based on gene-edited T cells. The company's market capitalization is $197.686 million, and its latest stock price is $1.98. Analysts have a strong buy rating on CLLS, with a target price of $7.13.
Company Overview
Cellectis SA is headquartered in Paris, France, and is focused on developing CAR-T cell therapies for the treatment of cancer. The company has a pipeline of clinical-stage candidates, including UCART19, which is being evaluated in a Phase II trial for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).
Fundamental Analysis
Cellectis SA's financial performance has been mixed in recent quarters. The company reported revenue of $36.042 million in the last twelve months (LTM), a 9.98% increase year-over-year. However, the company's net loss widened to $67.222 million in the LTM, compared to a loss of $56.65 million in the prior year period. This resulted in a diluted EPS of -$1.16 in the LTM.
Technical Analysis
Cellectis SA's stock price has been trading in a range between $1.70 and $3.773 over the past 52 weeks. The stock is currently trading below its 50-day and 200-day moving averages, indicating a bearish trend. The relative strength index (RSI) is also below 50, suggesting that the stock is oversold.
Short Term Outlook
In the short term, Cellectis SA's stock price is likely to remain under pressure. The company's financial performance has been disappointing, and the technical indicators are bearish. However, the company's pipeline of clinical-stage candidates has the potential to drive future growth.
Long Term Outlook
In the long term, Cellectis SA's stock price has the potential to appreciate significantly. The company's CAR-T cell therapies have the potential to be a major breakthrough in the treatment of cancer. If the company's clinical trials are successful, it could become a major player in the immuno-oncology market.
Analyst Recommendations
Analysts have a strong buy rating on Cellectis SA. The average analyst target price is $7.13, which represents a potential upside of over 260% from the current price.
